Ankastim

N/A

Report date: 2025/03/14 16:54:43

Base Information

Drug NameAnkastim

Drug Alias NamemHsp70-targeted allogeneic NK cell therapy (Alphageneron Pharmaceuticals)allogeneic NK cell therapy (Alphageneron Pharmaceuticals)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyBiologics > Exosomes

Mechanisms of ActionHSP70 heat-shock proteins modulators

TargetsHSP70 heat-shock proteins

Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAlphageneron Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesAlphageneron Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[4]

Inactive IndicationsN/A

Other Information

ATC CodeN/A